Randal A. Hassler
Nessuna posizione attualmente
Profilo
Randal A.
Hassler worked as Vice President-Facility Operations at Amgen, Inc. from 1995 to 2007.
He then worked as Chief Operating Officer, VP-Operations & Finance at Seattle Biomedical Research Institute from 2008 to 2014.
Later, he worked as Executive Vice President-Pharmaceutical Operations at Lundbeck Seattle BioPharmaceuticals, Inc. Mr. Hassler has a graduate degree from Colorado State University and an undergraduate degree from Indiana University.
Precedenti posizioni note di Randal A. Hassler
Società | Posizione | Fine |
---|---|---|
Seattle Biomedical Research Institute
Seattle Biomedical Research Institute Miscellaneous Commercial ServicesCommercial Services Seattle Biomedical Research Institute operates as a non-profit organization that researches and discovers infectious diseases. It provides research for new drugs, vaccines, and diagnostics. The company was founded by Kenneth D. Stuart and Ruth W. Shearer in 1976 and is headquartered in Seattle, WA. | Director of Finance/CFO | 01/01/2014 |
AMGEN INC. | Corporate Officer/Principal | 01/01/2007 |
ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formazione di Randal A. Hassler
Colorado State University | Graduate Degree |
Indiana University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
AMGEN INC. | Health Technology |
Aziende private | 2 |
---|---|
Seattle Biomedical Research Institute
Seattle Biomedical Research Institute Miscellaneous Commercial ServicesCommercial Services Seattle Biomedical Research Institute operates as a non-profit organization that researches and discovers infectious diseases. It provides research for new drugs, vaccines, and diagnostics. The company was founded by Kenneth D. Stuart and Ruth W. Shearer in 1976 and is headquartered in Seattle, WA. | Commercial Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
- Borsa valori
- Insiders
- Randal A. Hassler